Revive BioShield II: Bring Big Pharma Back Into Medical Countermeasures

The legislative architect of BioShield II proposal that failed to make it into law in 2005 argues that the proposal remains the best approach for bringing experienced, well-funded medical product companies into the effort to protect the nation against bioterror attacks -- from other governments and from nature.

The bottom line is clear: The biosecurity strategies – particularly for medical countermeasures (MCM) development – of the Clinton and Bush Administrations have been grossly inadequate, even a scandal. The question here is whether these failures will continue with the Obama Administration.

In December of 2001, less than two months after the anthrax attacks, Senators Joe Lieberman (Independent Democrat, CT) and Orrin...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet